Drug Discovery Processes

Tecan

Supporting the progression of phenotypic hits with bioactivity profiling

4 June 2018 | By Drug Target Review

Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.

Tech note: Long term live cell imaging in a high-content system

29 May 2018 | By PerkinElmer

How to perform successful long term live cell imaging in a high-content analysis system.

Charles River Laboratories announces extended relationship with The Michael J. Fox Foundation

18 May 2018 | By Charles River Laboratories

Extension includes new project to phenotype Parkinson’s disease models and the continuation of LRRK2 research.

Charles River Laboratories expands services for early discovery screening

18 May 2018 | By Charles River Laboratories

Addition of high-throughput technologies and expanded pharmacokinetic services enhances existing support for small molecule drug discovery.

SB216763 shows preclinical efficacy in Rett syndrome

16 May 2018 | By Drug Target Review

Researchers describe how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome...

ELRIG UK hosts inaugural Discovery Technologies event

8 May 2018 | By ELRIG

ELRIG (European Laboratory Research & Innovation Group) has announced its first Discovery Technologies meeting, which will take place at Alderley Park, located near Macclesfield in Cheshire.

FoxM1 gene provides promising target for pulmonary hypertension

2 May 2018 | By Dr Zara Kassam (Drug Target Review)

The FoxM1 gene will drive the development of new drugs to reverse a process called vascular remodelling - a key feature in pulmonary hypertension...

Transforming translational research: CANscript^TM – A better predictive model for oncology

27 April 2018 | By Mitra Biotech

In this webinar, speaker Mark Paris, PhD discussed a recent study evaluating a cohort of HNSCC patient tumours treated with anti-PD1 using CANscript TM;. He also be reviewed the results of this study as a means of investigating predictors of clinical response and identifying mechanisms of resistance.

Automated assessment of Liver and Cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays

27 April 2018 | By TECAN

ABOUT THIS WEBINAR: In this two-part webinar, both automation of P450 (CYP) assays and the automatisation of cellular differentiation processes and compound testing using human induced pluripotent stem cells based assays was covered.   Metabolism of drugs is a key factor in compound toxicity, and automated assays which monitor inhibition or…

Biomarker endpoints for Parkinson’s disease

26 April 2018 | By Charles River Laboratories

This webinar provides a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.

in vitro phenotypic assays for Parkinson’s disease

26 April 2018 | By Charles River Laboratories

This webinar highlights cell based assays for Parkinson’s disease that include endpoints such as a-synuclein aggregation and mitophagy readouts.

Mitra Biotech

Animal model of Huntington’s offers advantages for testing treatments

2 April 2018 | By Dr Zara Kassam (Drug Target Review)

Using genetic engineering technology, a team of scientists have established an animal model of Huntington's disease...

I-BET-762 may stop cancer-causing gene in its tracks

28 March 2018 | By Dr Zara Kassam (Drug Target Review)

Scientists are testing a promising drug that may stop a gene associated with obesity from triggering breast and lung cancer...